Abstract
Cyclin-dependent kinase 5 (cdk5) is a member of the serine-threonine kinase family of cyclin-dependent kinases. This family is known for its role in the cell cycle, but cdk5 differs due to its interaction with activators p35 or p39, both abundant in post-mitotic neurons. Cdk5 is not known to have a role in cell cycle regulation at all, but is known to be an important modulator of neuronal activity. Cdk5 has been an attractive target for CNS diseases for a number of years. Among its attractions is the possibility that inhibitors will prevent the pathological phosphorylation of tau and neurofibrillary pathology in both Alzheimers disease and tauopathies. More recently, there has been evidence that cdk5 is involved in the processing of pain and therefore inhibitors would also have potential therapeutic value for acute pain. Several classes of potent chemical inhibitors for cdk5 have been identified but most are competitive with the ATP binding site, resulting in a lack of specificity among the other cyclin-dependent kinases as well as other ATP-dependent kinases. We are working to discover specific inhibitors that might disrupt the interaction of tau and cdk5 at sites other than the ATP binding site. We are screening our compound library of 110,000 compounds using the full length tau as a substrate and will separate ATP competitive from non-competitive binders. In addition, we are taking a computational approach with virtual screening to identify non-ATP-competitive binders. These two approaches may lead to the discovery of sitespecific inhibitors for tau and cdk5 interactions rather than competitive inhibitors for ATP binding. The hope is that non- ATP competitive compounds will more likely be selective and will be better therapeutics.
Keywords: ATP binding pocket, ATP competitors, Neurodegeneration, CNS diseases, Cyclin-dependent kinase 5
Current Alzheimer Research
Title: New Approaches to the Discovery of cdk5 Inhibitors
Volume: 4 Issue: 5
Author(s): Marcie A. Glicksman, Gregory D. Cuny, Min Liu, Brittany Dobson, Kenneth Auerbach, Ross L. Stein and Kenneth S. Kosik
Affiliation:
Keywords: ATP binding pocket, ATP competitors, Neurodegeneration, CNS diseases, Cyclin-dependent kinase 5
Abstract: Cyclin-dependent kinase 5 (cdk5) is a member of the serine-threonine kinase family of cyclin-dependent kinases. This family is known for its role in the cell cycle, but cdk5 differs due to its interaction with activators p35 or p39, both abundant in post-mitotic neurons. Cdk5 is not known to have a role in cell cycle regulation at all, but is known to be an important modulator of neuronal activity. Cdk5 has been an attractive target for CNS diseases for a number of years. Among its attractions is the possibility that inhibitors will prevent the pathological phosphorylation of tau and neurofibrillary pathology in both Alzheimers disease and tauopathies. More recently, there has been evidence that cdk5 is involved in the processing of pain and therefore inhibitors would also have potential therapeutic value for acute pain. Several classes of potent chemical inhibitors for cdk5 have been identified but most are competitive with the ATP binding site, resulting in a lack of specificity among the other cyclin-dependent kinases as well as other ATP-dependent kinases. We are working to discover specific inhibitors that might disrupt the interaction of tau and cdk5 at sites other than the ATP binding site. We are screening our compound library of 110,000 compounds using the full length tau as a substrate and will separate ATP competitive from non-competitive binders. In addition, we are taking a computational approach with virtual screening to identify non-ATP-competitive binders. These two approaches may lead to the discovery of sitespecific inhibitors for tau and cdk5 interactions rather than competitive inhibitors for ATP binding. The hope is that non- ATP competitive compounds will more likely be selective and will be better therapeutics.
Export Options
About this article
Cite this article as:
Glicksman A. Marcie, Cuny D. Gregory, Liu Min, Dobson Brittany, Auerbach Kenneth, Stein L. Ross and Kosik S. Kenneth, New Approaches to the Discovery of cdk5 Inhibitors, Current Alzheimer Research 2007; 4 (5) . https://dx.doi.org/10.2174/156720507783018181
DOI https://dx.doi.org/10.2174/156720507783018181 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Respiration and Energy Homeostasis
Current Respiratory Medicine Reviews Sleep Apnea: an Underestimated Cause of Resistant Hypertension
Current Hypertension Reviews Antioxidant Therapy Alters Brain MAPK-JNK and BDNF Signaling Path-ways in Experimental Diabetes Mellitu s
Current Neurovascular Research Reviewing the Role of Resveratrol as a Natural Modulator of Microglial Activities
Current Pharmaceutical Design The Role of the Immune System in the Pathogenesis of Hypertension
Current Hypertension Reviews ApoE ε4 Allele Related Alterations in Hippocampal Connectivity in Early Alzheimer’s Disease Support Memory Performance
Current Alzheimer Research Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy
Current Topics in Medicinal Chemistry Mitochondrial Dysfunction in Depression
Current Neuropharmacology The Impact of Metabolic Disease Associated with Metabolic Syndrome on Human Pregnancy
Current Pharmaceutical Biotechnology Co-Morbid Erectile Dysfunction (ED) and Antidepressant Treatment in a Patient – A Management Challenge?
Current Drug Targets Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Current Alzheimer Research Editorial (Thematic Issue : What is Language? Different Viewpoints)
Neuroscience and Biomedical Engineering (Discontinued) Mitochondrial Dysfunction and Oxidative Stress in Insulin Resistance
Current Pharmaceutical Design The Association between Depression and Gastroesophageal Reflux based on Phylogenetic Analysis of miRNA Biomarkers
Current Medicinal Chemistry Evaluation of Small Molecule Tuberculostats for Targeting Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
Current Medicinal Chemistry Serum Amyloid Beta Peptides in Patients with Dementia and Age-Matched Non-Demented Controls as Detected by Surface-Enhanced Laser Desorption Ionisation-Time of Flight Mass Spectrometry (SELDI-TOF MS)
Current Clinical Pharmacology Zebrafish as a Model Organism to Study Melatonin Mechanisms and Treatments
Current Psychopharmacology Opioids: Other Routes for Use in Recovery Room
Current Drug Targets The Pluripotential Effects of Hypolipidemic Treatment for Polycystic Ovary Syndrome (PCOS): Dyslipidemia, Cardiovascular Risk Factors and Beyond
Current Pharmaceutical Design